(why did you invest)
I will take that one (this is from several months ago,
happily I didn't pay much attention until the stock
made it's tax-loss bottom recently) The full press
release regarding the sale to OSI is in post 20
...and thanks Rick.
Cadus will retain ownership of all its other assets,
including its core yeast technology for developing drug
discovery assays, its collection of over 25,000 proprietary
yeast strains, human and mammalian cell lines, and genetic
engineering tools, its program to identify and isolate human
orphan G protein-coupled receptors and elucidate their function,
its proprietary software, its genomics databases related to
G protein-coupled receptors, the LivingChip(TM) program, all
assays and technologies reverting to Cadus from its collaboration
with Bristol-Myers Squibb Company, a 30% equity position in Axiom
Biotechnologies Inc., the company's current cash and cash
equivalents, and the approximately $18.7 million being held
in escrow pending appeal of the verdict in favor of SIBIA
Neurosciences, Inc. (''SIBIA''). |
